<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; } </style>

United States // News Releases

News Releases

INVESTOR RESOURCES
Filter Releases
 
News Releases
Date Title and Summary View
May 2, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John Onopchenko as the Company's Chief Executive Officer, effective immediately. Dan Lemaitre, Chairman of the Bo...
May 2, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2018. "Our top-line performance during the first quarter reflects slightly bett...
Apr 25, 2018
Results Presented Today in Late-Breaking Aortic Trials Session at Charing Cross International Symposium IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the results of a study, w...
Apr 3, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2018 after the market close on Wednesday, May 2, 2018. The Company's management will ...
Mar 19, 2018
Company to Host Investor Conference Call on March 20, 2018 at 8:30 a.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global analysi...
Mar 5, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS2 IDE Confirmatory Clinical Study of the investigational Nellix® EndoVascular Aneurysm Sealing (EVAS) System b...
Feb 21, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott is stepping down as the Company's Chief Executive Officer. To facilitate a smooth transition, Mr. McDermott has committed to remaining in his...
Feb 21, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017. "While our top-line performance during the fourth quarter fini...
Feb 5, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today the completion of enrollment in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study...
Jan 30, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Leerink Partners 7th Annual Global Health...
Jan 29, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Greg Morrow as the Company's Chief Marketing Officer, effective immediately. Mr. Morrow brings to Endologix a weal...
Jan 25, 2018
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2017 after the market close on Wednesday, February 21, 2018. The Company's manageme...
Dec 19, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the 36th Annual J.P. Morgan Healthcare Confe...
Nov 14, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present at the Piper Jaffray 29th Annual Healthcare Conference at 2:50 p.m. ET on Wednesday, November...
Nov 7, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017. "Third quarter results were in line with our expectations, despite wea...
Page:
2
...
17
Next Last
 
= add release to Briefcase